QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 envveno-medical-to-file-supervisory-appeal-after-fda-rejects-venovalve-premarket-approval-application

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

 envveno-medical-announces-fda-not-approvable-decision-on-venovalve-pma-submission

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

 envveno-medical-corporation-releases-preliminary-findings-from-venovalve-health-economic-study-which-indicate-that-the-venovalve-would-be-a-cost-effective-treatment-option-for-patients-with-severe-chronic-venous-insufficiency-caused-by-deep-valvular-incompetency

Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower co...

 envveno-medical-to-present-interim-two-year-follow-up-data-on-42-subjects-from-75-person-venovalve-us-pivotal-trial-at-svs-vam25

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continu...

 envveno-medical-announces-that-its-manuscript-titled-three-year-outcomes-of-surgical-implantation-of-a-novel-bioprosthetic-valve-for-the-treatment-of-deep-venous-reflux-has-been-published-in-the-in-the-peer-reviewed-journal-annals-of-vascular-surgery

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe an...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION